High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma

Background: Immunotherapy targeting PD-1/PD-L1 represents a breakthrough in the treatment of lung cancer. Pyruvate kinase M2 (PKM2) is not only a critical player in glycolysis, but also conducive to tumor progression and immune response. While both have been linked to lung adenocarcinoma (AC), the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Long, Chen, Mengxi, Yuan, Yu, Ming, Alex Lau, Guo, Wei, Wu, Kaisong, Chen, Honglei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255362/
https://www.ncbi.nlm.nih.gov/pubmed/32489463
http://dx.doi.org/10.7150/jca.42610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255362/
https://www.ncbi.nlm.nih.gov/pubmed/32489463
http://dx.doi.org/10.7150/jca.42610

Ejemplares similares